Badr El Khouzai (@BElkhouzai) profile picture

Radiation oncologist @UniPadova | #pcsm #hncsm #radonc

Joined May 2019
Badr El Khouzai retweeted
Across 3 prospective studies, the signal for post-prostatectomy SBRT in 5 fx is increasingly consistent: feasible, low toxicity & excellent in-field control. StereoBed randomized data show no PRO/toxicity penalty; POPART/esSBRT show few local failures. #ASTRO26 @rtdess @HimanshuNagarMD @RadOncDocJ @NRGonc @ASTRO_org @urotoday @ChadTangMD @TylerSbrt @SbrtSean @jryckman3 @seanmmcbride
2
33
1
72
4,331
Badr El Khouzai retweeted
An honour to present the efficacy results of #PACE_A in the plenary and sexual function in the LBA at #ASTRO26 Take home message-give patients the data, let them make an informed choice
4
40
1
102
4,596
Woke up to see the @QuadShotNews mentioning new @myESMO guidelines for prostate cancer. Congrats to @PBlanchardMD @stefanofanti4 @Silke_Gillessen @Prof_Nick_James @piet_ost @PCaParker @Tilki_De @alison_tree @ZilliThomas et al on this Oscar of Oncology award from USA 🇺🇸 😀👏
1
13
2
41
4,083
Badr El Khouzai retweeted
Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT6…. The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.
11
52
8
139
14,317
🚨 New @TheLancet Seminar: #ProstateCancer🚨 Key takeaways ⬇️ 🧬 Biology & heterogeneity matter Prostate cancer isn’t one disease—molecular subtypes (eg, BRCA2, PTEN, AR alterations) increasingly guide therapy 🔍 Diagnosis has evolved MRI-first pathways + PSMA PET outperform conventional imaging, but raise questions about stage migration ⏸️ Active surveillance is standard Preferred for low-risk disease and select intermediate-risk pts—reduces overtreatment with excellent long-term outcomes 🏥 Local therapy ≈ equivalent cancer control Surgery, EBRT, brachytherapy all effective—decision hinges on toxicity profiles & patient preferences 🔥 High-risk disease = multimodal RT + long-term ADT ± ARPIs now core; surgery often part of a combined strategy 🌍 Metastatic landscape transformed ADT + ARPI (± docetaxel) improves OS; triplet therapy for fit, high-volume pts 🎯 Targeted & radioligand therapies PARP inhibitors (BRCA-driven benefit) and Lu-177–PSMA are reshaping mCRPC care 🤝 Shared decision-making is central Toxicity, quality of life, and sequencing remain key unanswered questions Essential read for anyone treating prostate cancer 👇 @PCF_Science @PCFnews @urotoday @UrologyTimes @Ecastromarcos @alison_tree 🔗shorturl.at/xZti6
28
92
7,968
Replying to @h_mehanna
@h_mehanna @H_N_C_I_G presents results of CompARE trial at #ESMO26 on the use of induction and adjuvant durvalumab to concurrent CRT for oropharyngeal cancer. No benefit overall in DFS or OS. possible benefit in high risk patients. No added toxicity.
2
5
10
454
STOPCAP at #ESMO26 Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS. Restricted to <5 bone or low volume mets on conventional imaging. No interaction with other patient/tumor characteristics.
3
52
110
4,973
🧬 Cribriform architecture changes the story in localized prostate cancer. 🔥 ProtecT 15-year biopsy re-review shows who really needs treatment vs surveillance. 🎯 n = 712 with available slides (13 % cribriform+) 💊 Arms: ▫️ Active monitoring ▫️ Radical prostatectomy ▫️ Radiotherapy + neoadjuvant ADT 📊 Key Results • Cribriform + → ↑ metastasis risk (HR 3.61, 95 % CI 1.60-8.11) • RT + ADT → lowest metastasis (HR 0.35 vs active monitoring) • Surgery → HR 0.52 vs active monitoring (NS) • 15-yr metastasis (cribriform +): AM 25 % | Surg 26 % | RT + ADT 8 % • Cribriform –: 7 % | 4 % | 3 % ✅ Takeaway: Cribriform + = treat aggressively (RT + ADT best long-term control) Cribriform – = active surveillance still safe for most patients. 📖 Sushentsev et al. JAMA Oncology 2025. 🔗 doi.org/10.1001/jamaoncol.20… #OncoTwitter #MedTwitter #ProstateCancer #UroOnc @OncoAlert @myesmo @esmo_open @ASCO @JAMAOnc
2
75
3
167
16,201
De escalated therapy is safe for stage IIA-IIB seminoma! ✅No recurrence since initial presentation in 2021. ✅No severe toxicity. ✅Secondary malignancies only outside of radiotherapy fields. Long term outcomes of SAKK 01/10 by @Alex_Papachris at #ESMO2
2
46
96
4,273
Badr El Khouzai retweeted
The RAMPP trial has landed ‼️ Congratulations to the authors for this great work!! It compared best systemic therapy + RP (with extended LND) to BST alone for patients with de-novo synchronous oligometastatic PCa, defined as =< 5 bone mets. BST consisted of lifelong ADT. It closed early due to STAMPEDE results. Cancer-Specific mortality was the primary enpoint. Clinical progression and OS were secondary endpoints. An X-torial 1/n @euplatinum @urotoday @dr_coops @chapinmd @pcaparker @soum_roy_radonc @drspratticus @drandrewloblaw @tylersbrt @seanmmcbride @sbrtsean @alison_tree @vedangmurthy @piet_ost @paulsargos @jryckman3 @5_utr @protonstorey @docpriyamvada @_shankarsiva @alexsherrymd @albertobossial @xristodouleas @amarukishan @zklaassen_md @themednet #OncoTwitter #ProstateCancer #RadOnc #UroOnc @oncoalert sciencedirect.com/science/ar…
7
19
2
45
20,971
STORM-PEACE V trial reported by @ZilliThomas #ESTRO25 Pelvic ENI superior to MDT for pelvic relapses after local Tx for #prostate cancer (6mo ADT each) Improves Biochemical PFS Locoregional PFS MFS ADT free survival Tox NS ENI clear SOC Online @TheLancetOncol Cc @piet_ost
1
40
1
107
8,272
SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (R1, PNI..): Julian Biau reports the STEREOPOSTOP GORTEC 2017-03. Convenient Fast Similar outcomes than post op brachy Mostly VMAT homogeneous plans #ESTRO25
9
56
4
138
12,167
Badr El Khouzai retweeted
Bladder preservation is a philosophy—not just a protocol. A 15-year journey in bladder preservation at @RadOncTMC . @TataMemorial @ACTREC_TMC From pioneering Adaptive Radiotherapy (ART) to safely transitioning to hypofractionation, our story, in @IJROBP #RadOnc #bladdercancer
6
72
4
222
19,680
Badr El Khouzai retweeted
Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (> 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. @RO_GreenJournal @masatoshihotta @UCLA sciencedirect.com/science/ar…
4
55
4
145
14,352
Thanks to @DavidSherMD for the invitation to contribute to this special issue in Seminars in Radiation Oncology on #precisionradiotherapy Personalising #NasopharyngealCancer #NPC : Systemic Therapy and Radiotherapy sciencedirect.com/science/ar…
1
13
1
48
5,716
Badr El Khouzai retweeted
Timing matters? ⏰ Morning ☢️⬆️ survival in NPC without added toxicity. Should we rethink RT scheduling? 🤔@OncoAlert 🎯Objective: •Investigate the impact of ☢️ timing (morning, afternoon, night) on OS and toxicity in NPC 🔬Methods: •Retrospective analysis of 1,040 NPC 👥 treated w/ IMRT •👥 grouped by treatment ⌚: Morning (6:00-11:59), Afternoon (12:00-17:59), Night (18:00-24:00) •PSM and Cox used to ⚖️ confounders 📊Results: •Morning RT ⬆️ OS •HR: Afternoon (5.88, P=.004), Night (4.81, P=.018)😱 •N🚫 difference in acute toxicity between groups 🗣Conclusion: Morning ☢️ ⬆️survival for NPC. Prospective studies are needed to confirm findings❗️
8
21
3
76
9,729
PEACE-1 RT is now published online at @TheLancet Some differences with STAMPEDE Key messages: RT to prostate in M1 #prostatecancer 1. improves rPFS but not OS in low volume 2. improves CRPC-FS & reduces serious GU SAE irrespective of volume Full text: thelancet.com/journals/lance…
5
94
1
206
14,641
Badr El Khouzai retweeted
Delighted to share the results of #PACE B trial, published in @NEJM today 5 fraction SBRT is non inferior to CRT! nejm.org/media/doi/full/10.1… @alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa
26
159
20
351
65,458